Qube Research & Technologies (QRT)
BCRX icon

Qube Research & Technologies (QRT)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,164,162
Closed -$16.9M – 3539
2025
Q4 		$16.9M Sell
2,164,162
-246,200
-10% -$1.78M 0.02% 1008
2025
Q3 		$18.3M Buy
2,410,362
+36,873
+2% +$307K 0.02% 940
2025
Q2 		$21.3M Buy
2,373,489
+1,432,824
+152% +$13.3M 0.02% 846
2025
Q1 		$7.05M Buy
940,665
+667,821
+245% +$5.39M 0.01% 1346
2024
Q4 		$2.05M Buy
272,844
+18,943
+7% +$144K ﹤0.01% 1868
2024
Q3 		$1.93M Buy
+253,901
New +$1.93M ﹤0.01% 1774
2024
Q2 		– Sell
-667,394
Closed -$3.39M – 3820
2024
Q1 		$3.39M Sell
667,394
-361,109
-35% -$2.03M 0.01% 1449
2023
Q4 		$6.16M Buy
+1,028,503
New +$5.96M 0.01% 934
2023
Q3 		– Sell
-214,095
Closed -$1.51M – 4091
2023
Q2 		$1.51M Buy
+214,095
New +$1.72M 0.01% 1156
2021
Q3 		– Sell
-40,503
Closed -$640K – 2209
2021
Q2 		$640K Sell
40,503
-5,749
-12% -$78.1K 0.01% 1152
2021
Q1 		$470K Buy
+46,252
New +$477K 0.01% 1218
2020
Q3 		– Sell
-220,891
Closed -$1.05M – 1684
2020
Q2 		$1.05M Buy
+220,891
New +$882K 0.02% 847
2020
Q1 		– Sell
-14,836
Closed -$51K – 1141
2019
Q4 		$51K Buy
+14,836
New +$37.3K ﹤0.01% 1480

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Qube Research & Technologies (QRT)'s BCRX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 2,164,162 shares — an estimated $16.9M sold.

Qube Research & Technologies (QRT) first reported a position in BCRX in Q4 2019 and held it in 13 quarters. The position peaked at $21.3M in Q2 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 2,164,162 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $16.9M.
  • Qube Research & Technologies (QRT) first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 13 quarters.
  • Qube Research & Technologies (QRT)'s BioCryst Pharmaceuticals position peaked at $21.3M in Q2 2025.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.